WIN 55212-2 mesylate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526795

CAS#: 131543-23-2

Description: WIN 55212-2 is a CB1 agonist (cannabinoid receptor agonist). WIN 55212-2 impairs contextual fear conditioning through the activation of CB1 cannabinoid receptors. Win 55212-2 attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. WIN 55212-2 inhibits neurogenic inflammations in airway tissues.

Price and Availability


USD 450
USD 2450

USD 750
USD 3850

USD 1550

WIN 55212-2 mesylate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide).

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 526795
Name: WIN 55212-2 mesylate
CAS#: 131543-23-2
Chemical Formula: C28H30N2O6S
Exact Mass:
Molecular Weight: 522.616
Elemental Analysis: C, 64.35; H, 5.79; N, 5.36; O, 18.37; S, 6.13

Related CAS #: 131543-23-2 (mesylate)   131543-22-1 (free base)  

Synonym: WIN 55212-2; WIN55212-2; WIN-55212-2; WIN 552122; WIN552122; WIN-552122; WIN 55,212-2 mesylate

IUPAC/Chemical Name: [(3R)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-methanone, monomethanesulfonate


InChi Code: InChI=1S/C27H26N2O3.CH4O3S/c1-18-25(27(30)22-9-4-7-19-6-2-3-8-21(19)22)23-10-5-11-24-26(23)29(18)20(17-32-24)16-28-12-14-31-15-13-28;1-5(2,3)4/h2-11,20H,12-17H2,1H3;1H3,(H,2,3,4)/t20-;/m1./s1


Technical Data

White to off-white crystalline powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information

Related CAS#
131543-23-2 (WIN 55212-2 mesylate);
131543-22-1 (WIN 55212-2 free base).


1: Rodríguez-Arias M, Roger-Sánchez C, Vilanova I, Revert N, Manzanedo C, Miñarro J, Aguilar MA. Effects of Cannabinoid Exposure during Adolescence on the Conditioned Rewarding Effects of WIN 55212-2 and Cocaine in Mice: Influence of the Novelty-Seeking Trait. Neural Plast. 2016;2016:6481862. doi: 10.1155/2016/6481862. Epub 2015 Dec 31. PubMed PMID: 26881125; PubMed Central PMCID: PMC4736006.

2: Shabani M, Mahnam A, Sheibani V, Janahmadi M. Alterations in the intrinsic burst activity of Purkinje neurons in offspring maternally exposed to the CB1 cannabinoid agonist WIN 55212-2. J Membr Biol. 2014 Jan;247(1):63-72. doi: 10.1007/s00232-013-9612-1. Epub 2013 Nov 12. PubMed PMID: 24218023.

3: Pinar-Sueiro S, Zorrilla Hurtado JÁ, Veiga-Crespo P, Sharma SC, Vecino E. Neuroprotective effects of topical CB1 agonist WIN 55212-2 on retinal ganglion cells after acute rise in intraocular pressure induced ischemia in rat. Exp Eye Res. 2013 May;110:55-8. doi: 10.1016/j.exer.2013.02.009. Epub 2013 Feb 20. PubMed PMID: 23454099.

4: Shabani M, Divsalar K, Janahmadi M. Destructive Effects of Prenatal WIN 55212-2 Exposure on Central Nervous System of Neonatal Rats. Addict Health. 2012 Winter-Spring;4(1-2):9-19. PubMed PMID: 24494131; PubMed Central PMCID: PMC3905554.

5: Alonso-Alconada D, Alvarez A, Alvarez FJ, Martínez-Orgado JA, Hilario E. The cannabinoid WIN 55212-2 mitigates apoptosis and mitochondrial dysfunction after hypoxia ischemia. Neurochem Res. 2012 Jan;37(1):161-70. doi: 10.1007/s11064-011-0594-z. Epub 2011 Sep 11. PubMed PMID: 21909954.

6: Acheson SK, Moore NL, Kuhn CM, Wilson WA, Swartzwelder HS. The synthetic cannabinoid WIN 55212-2 differentially modulates thigmotaxis but not spatial learning in adolescent and adult animals. Neurosci Lett. 2011 Jan 10;487(3):411-4. doi: 10.1016/j.neulet.2010.10.067. Epub 2010 Nov 3. PubMed PMID: 21055447; PubMed Central PMCID: PMC3035942.

7: Shabani M, Hosseinmardi N, Haghani M, Shaibani V, Janahmadi M. Maternal exposure to the CB1 cannabinoid agonist WIN 55212-2 produces robust changes in motor function and intrinsic electrophysiological properties of cerebellar Purkinje neurons in rat offspring. Neuroscience. 2011 Jan 13;172:139-52. doi: 10.1016/j.neuroscience.2010.10.031. Epub 2010 Oct 20. PubMed PMID: 20969930.

8: Manzanedo C, Rodríguez-Arias M, Daza-Losada M, Maldonado C, Aguilar MA, Miñarro J. Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice. Behav Brain Funct. 2010 Mar 22;6:19. doi: 10.1186/1744-9081-6-19. PubMed PMID: 20307280; PubMed Central PMCID: PMC2858089.

9: Rodríguez-Arias M, Manzanedo C, Roger-Sánchez C, Do Couto BR, Aguilar MA, Miñarro J. Effect of adolescent exposure to WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):166-71. doi: 10.1016/j.pnpbp.2009.10.019. Epub 2009 Oct 30. PubMed PMID: 19883712.

10: Accorsi-Mendonça D, Almado CE, Dagostin AL, Machado BH, Leão RM. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors. Brain Res. 2008 Mar 20;1200:1-9. doi: 10.1016/j.brainres.2008.01.011. Epub 2008 Jan 16. PubMed PMID: 18308297.

11: Benagiano V, Lorusso L, Flace P, Girolamo F, Rizzi A, Sabatini R, Auteri P, Bosco L, Cagiano R, Ambrosi G. Effects of prenatal exposure to the CB-1 receptor agonist WIN 55212-2 or CO on the GABAergic neuronal systems of rat cerebellar cortex. Neuroscience. 2007 Nov 9;149(3):592-601. Epub 2007 Aug 19. PubMed PMID: 17916407.

12: Rawls SM, Gomez T, Raffa RB. An NMDA antagonist (LY 235959) attenuates abstinence-induced withdrawal of planarians following acute exposure to a cannabinoid agonist (WIN 55212-2). Pharmacol Biochem Behav. 2007 Mar;86(3):499-504. Epub 2007 Jan 20. PubMed PMID: 17306870.

13: Marchalant Y, Rosi S, Wenk GL. Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation. Neuroscience. 2007 Feb 23;144(4):1516-22. Epub 2006 Dec 18. PubMed PMID: 17178196; PubMed Central PMCID: PMC1852513.

14: Rawls SM, Tallarida RJ, Zisk J. Agmatine and a cannabinoid agonist, WIN 55212-2, interact to produce a hypothermic synergy. Eur J Pharmacol. 2006 Dec 28;553(1-3):89-98. Epub 2006 Aug 26. PubMed PMID: 17109846.

15: Rawls SM, Rodriguez T, Baron DA, Raffa RB. A nitric oxide synthase inhibitor (L-NAME) attenuates abstinence-induced withdrawal from both cocaine and a cannabinoid agonist (WIN 55212-2) in Planaria. Brain Res. 2006 Jul 12;1099(1):82-7. Epub 2006 Jun 19. PubMed PMID: 16782070.

16: Struik ML, Yazulla S, Kamermans M. Cannabinoid agonist WIN 55212-2 speeds up the cone response to light offset in goldfish retina. Vis Neurosci. 2006 Mar-Apr;23(2):285-93. PubMed PMID: 16638179.

17: Pamplona FA, Takahashi RN. WIN 55212-2 impairs contextual fear conditioning through the activation of CB1 cannabinoid receptors. Neurosci Lett. 2006 Apr 10-17;397(1-2):88-92. Epub 2006 Jan 6. PubMed PMID: 16406322.

18: Yoshihara S, Morimoto H, Ohori M, Yamada Y, Abe T, Arisaka O. The cannabinoid receptor agonist WIN 55212-2 inhibits neurogenic inflammations in airway tissues. J Pharmacol Sci. 2005 May;98(1):77-82. Epub 2005 May 12. PubMed PMID: 15888960.

19: Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF. Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler. 2004 Apr;10(2):158-64. PubMed PMID: 15124761.

20: Rawls SM, Tallarida RJ, Gray AM, Geller EB, Adler MW. L-NAME (N omega-nitro-L-arginine methyl ester), a nitric-oxide synthase inhibitor, and WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrro lo[3,2,1ij]quinolin-6-one], a cannabinoid agonist, interact to evoke synergistic hypothermia. J Pharmacol Exp Ther. 2004 Feb;308(2):780-6. Epub 2003 Nov 10. PubMed PMID: 14610231.